Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

There is no established second-line treatment for advanced pancreatic cancer after gemcitabine failure. In view of the urgent need for such therapy, and since preclinical and phase I clinical data suggest an encouraging, potentially synergistic activity between raltitrexed and irinotecan, the presen...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ulrich-Pur, H, Raderer, M, Verena Kornek, G, Schüll, B, Schmid, K, Haider, K, Kwasny, W, Depisch, D, Schneeweiss, B, Lang, F, Scheithauer, W
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2003
Témata:
Clinical
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2747555/
https://ncbi.nlm.nih.gov/pubmed/12698181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600883
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky